Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
While the top- and bottom-line numbers for TransMedics (TMDX) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
TransMedics (TMDX) delivered earnings and revenue surprises of -51.46% and -0.99%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
TransMedics Group unveiled its Controlled Hypothermic Organ Preservation System, or CHOPS, a new active cooling device for donor organ storage. The company outlined plans for CHOPS to serve as the control arm in the ENHANCE Heart Part B and DENOVO Lung clinical trials. These updates add a new organ preservation platform alongside TransMedics Group's existing transplant technology programs. TransMedics Group (NasdaqGM:TMDX) is drawing attention with CHOPS at a time when its share price...
Is TMDX a good stock to buy? We came across a bullish thesis on TransMedics Group, Inc. on Grillo Insights’s Substack by Eric García. In this article, we will summarize the bulls’ thesis on TMDX. TransMedics Group, Inc.’s share was trading at $116.11 as of April 15th. TMDX’s trailing and forward P/E were 23.84 and 46.51 respectively according to Yahoo Finance. […]
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.